Mitochondrial DNA (mtDNA) instability has been observed in different types of cancer, including colorectal, breast, and gastric cancer. The relationship between the occurrence of such alteration and the nuclear microsatellite instability (nMI) status of the neoplastic cells remains controversial. In an attempt to clarify this issue, we sequenced the first and second mtDNA hypervariable regions, and typed the mitochondrial (CA) n dinucleotide polymorphism in 69 patients with primary tumors of the central nervous system (CNS), previously screened for nMI. Tumor samples showed 27 D-loop sequence changes (39.1%) compared to the corresponding blood samples. Microsatellite homoplasmic allele mutations were detected in four cases (5.8%). We did not find significant associations of the mtDNA instability status with clinicopathological parameters including sex, age, tumor size, and duration of clinical course. Neither did we find any association between mtDNA and nuclear instabilities, indicating that, at least in CNS tumors, they respond to different DNA repair mechanisms. We have also compiled the mtDNA instabilities previously reported by other authors for several types of tumors, comparing them to mtDNA polymorphisms in human populations. Most of the tumor-associated changes are common human polymorphisms and mutational hotspots. To explain the molecular behavior of mtDNA instability in tumors, we propose a model also common to other biological situations.
In recent years, dysfunction of the nuclear DNA repair system has been proposed as a mechanism for carcinogenesis. Mutations in several genes involved in DNA replication and mismatch repair have been detected in several human cancers. This phenomenon, first recognized in hereditary nonpolyposis colorectal carcinoma (HNPPC; Aaltonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993) , was also reported later in other tumor types (Risinger et al., 1993; Yee et al., 1994; Field et al., 1995; Kiaris et al., 1995) . In tumors of the central nervous system (CNS), nuclear microsatellite instability (nMI; a term here use to define the presence of alleles of any kind in tumor tissue that are absent in the normal tissue from the same individual) has been observed in a number of studies at a rate between 3.1 and 76.0% for gliomas, 0-25.0% for meningiomas, and 0-18.2% for shwannomas (Sobrido et al., 2000) . Overall, the frequency of nMI in brain tumors is lower than that observed in HNPCC and other neoplasms with mutations in the mismatch repair genes, suggesting a different mechanism of instability in CNS tumors.
The finding of nuclear genomic instability in human cancer raises the question of whether malignant cells may also show instability in the mitochondrial genome and, if so, what is the relationship between both types of instabilities and what is their functional importance for the evolution of cancer cells.
The human mitochondrial DNA (mtDNA) genome is small (B16569 bp) and present at a high copy number (10 3 -10 4 ) per cell. It contains 37 genes, including the structural genes for 13 of the protein subunits of the oxidative phosphorylation system, as well as the 12S and 16S rRNA genes, and 22 tRNAs. Mitochondrial genes are organized continuously with almost absence of noncoding intervening sequences except for a small segment called the displacement loop (D-loop), which contains regulatory elements controlling both replication and transcription of mtDNA.
In 1998, Habano et al. described alterations in a polycytosine (C) n tract within the D-loop region in 20% of colorectal carcinomas. Such mutations were located between positions 303-309 and 311-315 of the second hypervariable region (HVS-II), here referred to as the HVS-II poly-C tract (numbering according to the reference sequence CRS; Andrews et al., 1999) . These authors suggested that certain DNA repair systems, partly shared with the nuclear mismatch repair genes, might play a role in the maintenance of the mitochondrial genome in human cells. In 1998, Polyak et al. suggested that mitochondrial mutations may themselves affect mitochondrial function. The D-loop was also found to be a mutational hotspot in the bladder, lung, and head and neck neoplasms by Fliss et al. (2000) . In agreement with Habano et al. (1998) and Polyak et al. (1998) , mutations in this region may also be related to the function of the D-loop as a regulatory site for both replication and expression of the mitochondrial genomes. According to these investigators, the homoplasmic condition of the tumoral cells may be a consequence of selective advantage during replication of the mutant somatic mtDNA. Alternatively, Coller et al. (2001) propose that the homoplasmy of mtDNA tumoral mutations arises by chance in tumor progenitor cells, without any selective advantage or tumorogenic role. Chinnery et al. (2002) suggested that random genetic drift is powerful enough to explain the fixation of rare mtDNA mutations during ageing, mtDNA disease, and cancer. In brain tumors, Kirches et al. (1999) found high sequence variability in astrocytic brain cancers, as well as a loss of the heteroplasmy present in normal cells. In 2001, the same group extended the study of the HVS-II poly-C tract to 55 gliomas, detecting instability in five (9%) of them. These authors suggested the existence of a common mechanism generating inherited mtDNA mutations and somatic mutations in gliomas, leaving the door open to the possibility that some mtDNA mutations might be responsible for the production of free radicals with a concomitant consequence for tumorogenesis. Note, however, that the unstable positions in the mtDNA of patient number 2 in their series suggest contamination with mtDNA from haplogroup U4 (authors' unpublished data).
One key question, therefore, remains: does cancer lead to instability or do mitochondrial alterations produce cancer as a consequence? The answer depends on the putative functional implications of tumorassociated mutations. Although this hypothesis is continually being tested by different experiments, no one has yet resolved the answer completely. We proposed a new test based on population data. If hotspots in the tumours correlate with those in populations, then this is evidence that the same mechanism might explain both patterns, which would argue against a causal role for mtDNA instability in tumorigenesis. In 1997, Khrapko et al. (analysing a short coding region fragment of 100 bp by mutational spectrometry) reported that different human tissues and cells contain a remarkably similar set of hotspot point mutations, without however making any connection with variation in populations.
In order to better understand the putative relationship between mtDNA variation and CNS cancer, as well as nuclear micro-and minisatellite instabilities, we have analysed mtDNA from 69 Spanish patients from Galicia (northwest) with primary tumors of the CNS. We have also compiled the mtDNA instabilities reported in the clinical literature, in order to compare them with mutations that are observed on the evolutionary time scale.
The series analysed in the present work comprised gliomas, meningiomas, and schwannomas. For each patient, formalin-fixed, paraffin-embedded tumor specimens, as well as 10-15 ml of peripheral blood samples were collected after obtaining written informed consent and appropriate permission from the Ethical Committee of the Hospital Clı´nico in Santiago de Compostela. The criteria for patient selection and sampling have been reported elsewhere (Sobrido et al., 2000) . Extraction of DNA from the tumoral tissue was carried out as in Sobrido et al. (2000) . The clinical and histological features of these cases are summarized in Table 1 . DNA purification was performed following the method proposed by Gall et al. (1993) , with some modifications for paraffin-embedded samples, and as in Salas et al. (2001) for blood samples. We first studied the mitochondrial (CA) n microsatellite extending from position 514 to 523 in the D-loop region, using primers and PCR conditions described by Bodenteich et al. (1992) . All the samples have been previously tested for nMI through the analysis of eight loci (Sobrido et al., 2000) . The nuclear HRAS1 minisatellite has also been studied in the blood samples from these patients (Vega et al., 2001) . The association of mitochondrial status (presence or absence of instabilities) with the clinicopathological parameters and with nuclear instability was evaluated by means of w 2 , Fisher's exact, or t-tests. In all cases, the significance level was set at 0.05. Haplogroup affiliation was inferred on the basis of the observed HVS-I motif, according to Richards et al. (2000) and Salas et al. (2002) (Table 2) .
We found three different mtDNA microsatellite alleles in our 69 samples series. A2 was present in 5.8% of patients, A3 in 87.0%, and A4 in 7.2%. Analysis of the corresponding tumor samples showed homoplasmic allele changes in three gliomas and one meningioma (5.8% of the samples). All the three gliomas exhibited a shift from allele A3 to A4, whereas the meningioma patient showed allele A4 in the blood sample and A3 in the tumor sample. According to the results obtained by Sobrido et al. (2000) , 11 of our samples exhibited changes in at least one nuclear microsatellite (15.9%), two of them showing a second altered locus (2.9%; Table 2 ). However, no correlation between nMI and the mitochondrial instability at this microsatellite could be detected.
The D-loop sequences of 27 tumors (39.1%) showed differences compared to the blood samples: 20 out of 53 gliomas (37.7%), five out of 11 meningiomas (45.5%), and two out of five schwannomas (40.0%). In all, 14 out of 33 mutations found (42.4%) were length heteroplasmies related to the HVS-II poly-C tract, eight changes were related to insertions or deletions in the same tract (24.2%), five involved other heteroplasmies (15.2%), four were dinucleotide single-step changes (12.1%), and two were point mutations (6.1%).
Comparing these results with the evolutionary literature, we found that the whole set of tumor-associated Neutral evolution of mtDNA mutations in tumors A Vega et al mutations were polymorphisms described in population samples of human mtDNA. Table 2 testifies to the high mutability of these sites on an evolutionary time scale. In particular, 1. the same mtDNA microsatellite alleles appear on many unrelated haplogroup backgrounds; 2. the same is true for variation within the homopolymeric tract changes; 3. the transition at position 152 appears in haplogroups H, L1b, J, T, and U6; 4. the transition at position 146 appears in haplogroups H, K, J, M*, and U6.
In a review of the clinical literature, we observed that this pattern is common to many other types of tumors. The D-loop is by far the most studied region. More than 80% of the tumor-associated variants in the control region are common polymorphisms in phylogenetic studies (data not shown). This is likely an underestimation of the real percentage since we are ignoring the possible presence of sequence artifacts (Bandelt et al., 2002; authors' unpublished data) . Not surprisingly, the most commonly found unstable positions in tumor studies are those which show the highest level of instability in human populations: the homopolymeric tract variants (including length heteroplasmy) in HVS-I (between positions 16 184 and 16 193) and in , and the dinucleotide system at positions 513-524. Within the group of hotspots are positions 16 189 in HVS-I, as well as 146, 150, 152, and 185 in HVS-II, all of them found to harbor mutations in our CNS tumor samples. These positions are at or near the top of the lists of hotspots recently constructed by Malyarchuk et al. (2002) and Bandelt et al. (2002) , the only exception being position 16 069, which cannot be regarded as a hotspot; it may evolve at about the average rate for HVS-I (Meyer et al., 1999) .
Regarding the coding-region somatic mutations compiled from the literature, B40% of them (excluding those which are known to alter mitochondrial function, mainly insertions and deletions) have also been detected in human population studies. This is not a negligible proportion if we consider that the evolutionary database for coding variants is still small (Ingman et al., 2000; Maca-Meyer et al., 2001; Herrnstadt et al., 2002) . A reconstruction of the phylogeny of these complete sequences using a network approach (Bandelt et al., 1995 (Bandelt et al., , 1999 combined with a reconstruction of the mutations allows us to examine the mutational spectra In our glioma series, there was one pilocytic astrocytoma, one pleomorphic xantoastrocytoma and one anaplasic ganglioglioma not considered in the tumor grade classification.
d Expressed as mean and standard deviation, in parentheses.
e Given the small number of cases in a given distribution and the wide distribution of tumor locations in gliomas, it was not possible to classify them into reasonable categories, and this parameter was excluded from statistical analysis. The intensity of the surrounding edema was evaluated on the CT scans. In the patient with multiple meningiomas, only one of the tumors was studied Neutral evolution of mtDNA mutations in tumors A Vega et al The mutation rate for length changes in both the HVS-II poly-C tract and the mtDNA microsatellite is about 120 times the average for the noncoding region (Table 3) . Tumor-associated point mutations in the present report show an evolutionary mutation rate, which ranges from 3 to 59 times higher than the noncoding region average. In summary, almost all the somatic mutations found in tumors are mutational hotspots previously detected in human population studies. Our data did not suggest any association between nuclear and mtDNA instabilities. Six samples displayed both mtDNA and nuclear instabilities, 22 samples had only the former, while five only the latter type of instability, and 36 samples had neither of them (P ¼ 0.334 in a two-tailed Fisher's exact test). Grouping both homopolymeric tract and microsatellite mutations in our sample, we found 20 (29.0%) cases with differences between blood and tumor. Alterations were found in 14 (26.4%) gliomas, five (45.5%) meningiomas, and one schwannoma (20.0%). For the same samples, the eight autosomal microsatellites previously studied by Sobrido et al. (2000) showed changes in 11 (15.9%) of the tumors: nine (17.0%) of the gliomas, two (40.0%) of the schwannomas, and none of the meningiomas. This indicates that for the mtDNA regions considered in the present study, there is a significantly higher rate of length variation in mtDNA compared to autosomal DNA (P ¼ 0.028 in a one-tailed Fisher's exact test). Among each specific tumor group, the most remarkable difference was in the group of meningiomas, since none of them showed autosomal microsatellite changes. This result, however, should be taken with caution because of the small number of meningiomas studied.
Consistent with the majority of tumor studies (with the exception of the gastric tumor study by Habano et al. (2000) ; but cf. the conflicting result for the same type of cancer from Ma´ximo et al. (2000) ), we found no correlation between nMI and D-loop changes. Furthermore, there was no evidence for correlation when the samples were classified by haplogroup background (Table 2) . Additionally, we did not find any significant association between the mtDNA instability status of tumors and clinicopathological parameters that included sex, age, tumor size, and duration of clinical course (Table 1) .
Our sample of CNS tumors also allowed us to investigate the relationship between mitochondrial alterations and tumor malignancy. Whereas gliomas are characterized by their tendency to progress through increasing stages of malignancy, meningiomas and schwannomas share a generally benign nature, slow growth, and well-demarcated tumor tissue. In total, 14 gliomas (26.4%) showed mtDNA changes compared to six (37.5%) meningiomas and schwannomas. These similar proportions suggest that instability in the mtDNA genome is not a good candidate for a marker of malignancy. Furthermore, within gliomas, tumors of grade II and those of grades III and IV had a similar distribution of somatic changes. The hypervariable regions HVS-I and HVS-II were amplified and sequenced for both blood and matched tumor samples in four overlapping fragments, according to the protocol described in Salas et al. (2001) . Each sample was sequenced at least twice, and those presenting any nucleotide difference between the constitutional and tumor tissues were re-extracted, reamplified, and sequenced at least four times. a Transitions in HVS-I and -II are recorded by their position in the CRS (minus 16 000 in HVS-I), while transversions are accompanied by a suffix specifying the variant base. HG ¼ haplogroup affiliation; HL ¼ length heteroplasmy in polycytosine tracts; MS ¼ mtDNA microsatellite allele, with nomenclature according to Bodenteich et al. (1992) ; AS ¼ astrocytoma; GB ¼ glioblastoma; GG ¼ ganglioglioma; MG ¼ meningioma; OA ¼ oligoastrocytoma; ODG ¼ oligodendroglioma; PX ¼ pleomorphic xantoastrocytoma; SW ¼ schwannoma. b mtDNA differences found between the blood sample and the counterpart tumors We thus propose that almost all the variants found in tumors in the present study and available literature are neutral to mitochondrial function, and are unlikely to influence tumorogenesis. Only a small percent of variants are involved in functional alterations, but these are neither a common factor to different kind of tumors nor private alterations of specific cancer types. This seems to indicate that none of these variants represent a common factor involved in some unknown programmed mechanism of tumorogenesis. The results of the present study, together with the phylogenetic examination of the evolutionary literature, support a general model that would display the following broad pattern in different types of tumors:
1. Homoplasmic mutations accumulate in the mtDNA genome as a consequence of (relaxed) random segregation of mutant molecules during tumor development, although other (non-neutral) mechanisms cannot be completely ruled out. 2. Mutations are more likely to affect those positions that mutate fastest on the evolutionary time scale, and are common polymorphisms in populations. These mutations do not provide selective advantage and are unlikely to contribute to tumorogenesis. 3. A small fraction of mutations (not specific to any type of tumor) may alter mtDNA function and cell physiology. These mitochondrial functional instabilities may contribute to tumor development, but are unlikely to be causal.
This model is in agreement with the finding of Coller et al. (2001) that the observed mtDNA homoplasmy can arise entirely by chance in tumor progenitor cells, without any physiological advantage or tumorigenic requirement (although they do not exclude a role for other mechanisms). It is also consistent with the hypothesis formulated by Chinnery et al. (2002) that there is a common mechanism involved in ageing, cancer, and mitochondrial disease, although on different time scales. Mutation generates instabilities mainly at hotspot sites. Genetic drift during relaxed replication is the main force responsible for their destiny, either fixation or elimination. This is concordant with the observation of Khrapko et al. (1997) that different human organs (colon, lung, and muscle, as well as their derived tumors) share nearly all mitochondrial hotspot point mutations. Additionally, this pattern of mutability seems to be common to other biological situations. Forster et al. (2002) observed that radiationassociated point mutations are evolutionary hotspots in the mtDNA genome. The model includes: (1) somatic differences between tissues of the same individual, including situations of forensic interest, where there are differences between fragments of the same hair-shaft (Salas et al., 2001; Tully et al., 2003) , (2) intergenerational mutations between mother and offspring, and (3) the generation of heteroplasmy in normal cells (Stoneking 2000) . In addition, this model would explain the lack of association between nMI (and malignancy) and mtDNA instability.
Although we have found evidence in support of this model, future studies will help to corroborate it. The features of mtDNA hypervariable sites that cause them to be mutational hotspots remain obscure. But even without a good model for this process, the presence of mutations at a selection of these hotspots in both coding and noncoding regions may be useful for tumor diagnosis, given that mtDNA instability exists in almost all the tumors analysed to date.
In the present report, we have also shown that the phylogenetic structure of mtDNA variation revealed in a population genetic context (Richards and Macaulay 2001 ) is a necessary framework to analyse the variation between tissues in an individual, and thus to understand the role that mtDNA variation might play in carcinogenesis. It is unfortunate that the clinical literature in this area does not routinely report comprehensive sequence results. This has two important consequences: (a) the phylogenetic interpretation of the structure of the mtDNA variants found is limited and (b) the phylogenetic proofreading of sequence data (e.g., Bandelt et al., 2002 ) cannot be carried out.
